Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.59)
# 821
Out of 4,966 analysts
84
Total ratings
54.41%
Success rate
23.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: In-Line | $3 → $2 | $3.28 | -39.02% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $51.83 | +91.01% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $17.50 | +157.14% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.31 | +44.40% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.57 | +94.55% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.22 | +225.58% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $33.49 | +4.51% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $437.85 | -17.78% | 9 | Aug 8, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $438 → $515 | $391.02 | +31.71% | 18 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $446.51 | -41.77% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.10 | +81.82% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $9.03 | +265.65% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $46.73 | -18.68% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $29.96 | +167.02% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.18 | +191.26% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.83 | +552.74% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $8.40 | +638.10% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.26 | +459.11% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $21.64 | +10.91% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $13.88 | +116.14% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.71 | +169.54% | 1 | Feb 5, 2020 |
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $3.28
Upside: -39.02%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $51.83
Upside: +91.01%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $17.50
Upside: +157.14%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.31
Upside: +44.40%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.57
Upside: +94.55%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.22
Upside: +225.58%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $33.49
Upside: +4.51%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $437.85
Upside: -17.78%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Outperform
Price Target: $438 → $515
Current: $391.02
Upside: +31.71%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $446.51
Upside: -41.77%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.10
Upside: +81.82%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $9.03
Upside: +265.65%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $46.73
Upside: -18.68%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $29.96
Upside: +167.02%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $6.18
Upside: +191.26%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.83
Upside: +552.74%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $8.40
Upside: +638.10%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.26
Upside: +459.11%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $21.64
Upside: +10.91%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $13.88
Upside: +116.14%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.71
Upside: +169.54%